Name: Equity Multiplier

Definition: The equity multiplier shows how much total assets the company controls for every dollar invested by shareholders. It reflects how much debt is being used to stretch owners’ equity. A higher multiplier means greater use of debt to amplify returns — but also amplifies risk if things go wrong. Lower multipliers suggest a safer, more self-funded business.

Interpretation:
• In '2021', NNNN's equity multiplier was 1.94, representing the level of financial leverage utilized. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2021' stood at 1.44.
• In '2022', NNNN's equity multiplier was 1.11, representing the level of financial leverage utilized. The decrease since '2021' reflects improving financial health. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2022' stood at 1.28. Industry average declined by 0.16 from previous year.
• In '2023', NNNN's equity multiplier was 1.07, representing the level of financial leverage utilized. The decrease since '2022' reflects improving financial health. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2023' stood at 1.10. Industry average declined by 0.18 from previous year.
• In '2024', NNNN's equity multiplier was 1.10, representing the level of financial leverage utilized. The increase compared to '2023' may signal growing financial pressure. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2024' stood at 0.92. Industry average declined by 0.18 from previous year.
Overall, NNNN's equity multiplier has been volatile but showed a downward trend over the past 4 years.

Formula: Equity Multiplier = Total Assets / Shareholders' Equity

Good Range: Usually ranges from 1.5 to 3 depending on industry.